Declining eGFR, Hyperkalemia, and a Cash-Paying Patient

Glipizide - stop. Two episodes of lightheadedness after missed meals is a clinical hypoglycemia signal. Sulfonylurea hypoglycemia risk rises steeply as eGFR falls, and the value of glipizide at an A1c of 9.2% is marginal. Stopping it is free, immediate, and removes the most acute safety hazard.

Metformin - reduce, do not simply continue. At eGFR 36 she is in the 30-45 band: initiation is not recommended and continued use requires dose reassessment with more frequent renal monitoring. A defensible move is reduction to 500 mg twice daily with eGFR recheck in 3 months, and a clear plan to stop if eGFR falls below 30 or if she develops an acute illness with dehydration. Also note the rate of decline - 52 to 36 in one year is roughly a 30% drop and deserves its own explanation: volume depletion, NSAID use, obstruction, or a renovascular component. Do not simply re-label it diabetic kidney disease.

Lisinopril - do not increase now. Potassium of 5.1 on an ACE inhibitor with eGFR 36 is a ceiling signal. Repeat the potassium to exclude hemolysis, review dietary potassium and salt substitutes (potassium chloride), and stop any hidden potassium sources. Continuing the current dose is reasonable if potassium is confirmed and stable; escalating the dose is not.

Atorvastatin - continue, but reassess intensity. Diabetes plus CKD is high risk; 40 mg is moderate intensity. Consider high-intensity dosing if tolerated and if she is not already at goal.

Also interrogate the A1c itself. An A1c of 9.2% after 6 kg of intentional weight loss is discordant. In advanced CKD, anemia, or altered red cell turnover, A1c can misrepresent glycemia in either direction. Ask about actual glucose readings and consider a CGM or fructosamine before intensifying therapy based on this number alone.

Sequencing principle: safety first, then outcome-modifying therapy, then glycemic intensification - and at every step choose the option that is both highest-value and actually affordable.

Change 1 (today): stop glipizide. Zero cost, removes hypoglycemia risk, and simplifies interpretation of subsequent glucose data. Nothing downstream can be assessed reliably while she is having sulfonylurea-related hypoglycemia.

Change 2 (today): reduce metformin to 500 mg twice daily, and address potassium. Also free. Confirm potassium with a repeat draw (avoid fist-clenching/hemolysis), eliminate salt substitutes and potassium supplements, and review her diet. Do not stack a new potassium-raising agent on a potassium of 5.1.

Change 3 (this visit or within 2 weeks): add an SGLT2 inhibitor. This is the highest-value addition and should be prioritized over any GLP-1 receptor agonist given cost: it slows CKD progression, reduces heart failure hospitalization and cardiovascular death, and lowers glucose modestly. Expect an eGFR dip of up to about 30% that is hemodynamic and not a reason to stop. Since she pays cash, do the practical work in the room: check generic availability and pharmacy-specific cash price, manufacturer patient assistance and copay programs, and 340B or clinic pharmacy pricing. If truly unaffordable, document that and move to the next-best covered option rather than abandoning the class silently.

What comes fourth, if needed: do not increase lisinopril while potassium is 5.1. For glycemic control after the above, the cheapest realistic option is basal insulin (NPH or glargine) or low-dose pioglitazone, with the caveats of hypoglycemia and edema/weight gain respectively. A GLP-1 receptor agonist would be ideal for weight and cardiovascular benefit, but with no coverage the honest plan is to pursue assistance programs and reassess at the next visit rather than commit her to a cost she cannot sustain.

Monitoring schedule:

• BMP in 1-2 weeks after the metformin change and any SGLT2 inhibitor start - potassium, creatinine, eGFR, bicarbonate. Repeat sooner (3-7 days) if potassium was confirmed at or above 5.5.
• Glucose log or CGM for 2-4 weeks, with particular attention to fasting values and any symptomatic episodes, so the next intensification is data-driven rather than A1c-driven.
• A1c in 3 months, interpreted alongside glucose data and with awareness that A1c is less reliable at this eGFR.
• Urine albumin-to-creatinine ratio in 3-6 months to track the effect of the SGLT2 inhibitor and ACE inhibitor.
• Annual (or sooner): dilated eye exam, comprehensive foot exam with monofilament, and a review of vaccinations including hepatitis B, pneumococcal, and influenza.
• Medication reconciliation at every visit with pill bottles, because cash-paying patients frequently ration or split doses.

Escalation triggers - spell these out for her in writing:

• Potassium 5.5 mmol/L or higher, or any rising trend: hold the ACE inhibitor, review diet, and evaluate for renal artery stenosis or adrenal causes if unexplained.
• eGFR fall greater than 30% from baseline or any acute kidney injury: hold metformin and the SGLT2 inhibitor during acute illness (sick-day rules), and investigate.
• Any symptomatic hypoglycemia: reassess regimen immediately.
• Weight loss that is unintentional, or new orthostasis, or a systolic pressure persistently below 100: reduce antihypertensives.
• Genital pain, swelling, or perineal tenderness on an SGLT2 inhibitor: evaluate for Fournier gangrene urgently.
• Volume depletion symptoms (vomiting, diarrhea, poor intake): sick-day plan - hold metformin, SGLT2 inhibitor, ACE inhibitor, and diuretics, and call.

Follow-up interval: return in 2-4 weeks to review labs and tolerability, then every 3 months until A1c and blood pressure are at goal and renal function is stable.